Navidea to present at BIO CEO conference
Navidea Biopharmaceuticals, producers of the amyloid PET agent NAV4694, announced Feb. 2 that CEO Mark Pikett, PhD, would hold a presentation at the 16th annual BIO CEO and Investor Conference taking place at the Waldorf Astoria in New York City, Feb. 10-11.
During his talk, Pykett will be discussing how the company is performing and providing an agenda for research and development and up and coming programs for commercialization. In the past year, Navidea saw the FDA approval of technetium 99m tilmanocept (Lymphoseek) and continues to develop NAV4694; NAV5001, also indicated for neurodegenerative diseases including Parkinson's and dementia with Lewy bodies; and RIGScan, a novel radiolabeled monoclonal antibody for oncologic imaging.
Pykett's speech is scheduled to take place Monday, Feb. 10, at 1:30 pm EST. The general public can listen in on the live webcast of his talk, which will be available for replay an hour after the live webcast for an estimated 30 days. Plug in to the webcast here.
The BIO CEO and Investor Conference is reputed to be the largest investment meeting focused exclusively on emerging and established biotech companies.